Merchavia Holdings And Investments Ltd · TASE:MRHL
Merchavia Holdings And Investments — Investor Presentation (April 2019)
49 slides from Merchavia Holdings And Investments's investor presentation, April 2019
Slide 1: Merchavia Holdings and Investments Ltd. Presentation for Investors - April 2019
Merchavia Holdings and Investments Ltd. Presentation for Investors - April 2019 1
Slide 2: A Forward-Looking Information
A Forward-Looking Information This presentation was prepared for summary and convenience only and is not intended to replace the need to review the reports issued by the Company to the public. Full and comprehensive information regarding the Company and its business can be found in the periodic and
Slide 3: Business card
Business card = XNA ipiest in Life
Slide 4: Business card
Business card | Merchavia An investment company specializing in investing in life science companies. The company has a strategic partnership with the innovation arm of the leading medical center in US - Cleveland Clinic. The company currently has 6 investments in companies targeted to markets which
Slide 5: The bottom line
The bottom line We believe that the life science market offers huge opportunities for the medium term and therefore that’s the company’s focus 5
Slide 6: Investment Strategy
Investment Strategy Business strategy: Targeted investment in promising companies with significant market potential, which target huge markets with clear demand for products, while rational risk management through the company's management, a scientific advisory committee and the innovation arm of th
Slide 7: The Board of Directors
The Board of Directors Erez Alroy Ephraim Gerlitz Ilan Goldstein Has served as director of SHL Manages the Goldstein family’s business Holder of a controlling interest in the company, Telemedicine since its establishment. dealings in Israel. Holds senior positions, certified lawyer (USA) with 40 yea
Slide 8: Members of the Scientific Advisory Committee
Members of the Scientific Advisory Committee Eldad Yassur Dr. Arnon Chait | USA Elhanan Streit | IL CEO of ARROW Israel. Arrow Electronics is Founder and CEO of Cleveland Diagnostics, Active in investments for several decades, a leading global distribution company that Inc. Has over 25 years of expe
Slide 9: Our Vision
Our Vision To make advanced medical technologies accessible through a public investment arm in Israel for the world's leading medical technologies 9
Slide 10: Our uniqueness
Our uniqueness Breakthrough innovation Professionalism Global networking A deep understanding The most innovative of the medical medical centers business world in the world 10
Slide 11: Strategic partner
Strategic partner About 3,400 Multidisciplinary physicians and 49,000 employees academic hospital scientists Centers in Florida, A non-profit A turnover of Nevada, Canada corporation about $7.2 billion and Abu Dhabi Merchavia has identified Cleveland Clinic as a business partner and gives priority t
Slide 12: How the investment is carried out?
How the investment is carried out? Discussion at the Detailed due diligence Convening of the Finding a company or Initial due performed by level of the Scientific Advisory Board of directors venture in Israel or diligence consultants and/or Company's Committee globally Cleveland Clinic management 12
Slide 13: Portfolio
| Portfolio Cleveland Diagnostics # cardiacsense (2 RMDY 13
Slide 14: Cleveland Diagnostics
CD» Cleveland Diagnostics g | MERCHAVIA 4 | Invest in Life
Slide 15: About the company
About the company An innovative and proven diagnostic technology platform intended for the diagnosis of cancer in the early stages using blood tests. A breakthrough technology that Innovative blood test for detects a change in the structure prostate cancer of the protein linked to diseases (differen
Slide 16: The investment
The investment 7.85% In February 2015 Merhavia invested $1 million according to company value of $10 million. The last financing round was performed in October 2018 - an internal financing round at a company value of $48 million. Currently Merchavia holds about 7.85% on a fully diluted basis. 16
Slide 17: Clinical status
Clinical status Multi-center clinical trial in the US, led by Dr. Eric Klein, head of the Glickman Urological & Kidney Institute at the Cleveland Clinic , medical center, who is considered a leading global expert in the field. The trial itself and the extension trial, which included about 500 males,
Slide 18: Manufacturing costs
Manufacturing costs The test production cost is very low (few dollars per unit) The test is also a technological platform for breast cancer, ovarian cancer, Alzheimer's disease and more.... A tremendous potential to change the structure of the market The possibility of replace the existing test (PSA
Slide 19: Significant milestone
Significant milestone Developing the platform and cooperating with strategic players for marketing and distribution. The company's strategy is to develop diagnostic products and cooperate with strategic players to market, commercialize and distribute the company's products. The prostate cancer test
Slide 20: The potential
The potential CDx develops on the basis of this breakthrough technology additional tests for breast cancer, lung cancer and Alzheimer's disease diagnosis. Each of these markets is a multi-billion dollar market 20
Slide 21: CardiacSense
i cardiacsense Watchin ver you MERCHAVIA 4 | Invest in Life INN
Slide 22: About the company
About the company CardiacSense develops wearable equipment (watches, bracelets, patches, etc.) which includes a number of highly advanced sensors, based on the illumination the body, processing the returns, and analysis using a unique algorithm developed in the company SpO₂ 1 Lead 1 Lead PPG Instant
Slide 23: The Technology
The Technology Continuous monitoring of arrhythmias (atrial fibrillation A-FIB), blood pressure, blood oxygen level, cardiac arrest, etc., is based on the illumination of light to the body and processing of the returning data CardiacSense Sensor 23
Slide 24: The investment
The investment 6% In June 2017 Merchavia invested $0.5 million in the company according to company value of $6 million. The last financing round was completed in April 2019 at a company value of $20 million. Currently Merchavia holds approximately 6% on a fully diluted basis. 24
Slide 25: Clinical status
Clinical status An initial clinical trial in An initial clinical trial in A preliminary clinical trial conducted in patients suffering from patients with cardiac March 2019, which included 24 subjects, atrial fibrillation was arrest was successfully compared heart rate indices obtained using success
Slide 26: Milestones
Milestones 1. Completion of a multicenter clinical trial in the field of A-FIB by the end of 2019. 2. Submission of application for medical device approval to CE in Europe by the end of 2019. 3. Submission of application for medical device approval to FDA in the US by the end of 2019. 4. Completion
Slide 27: 27
27
Slide 28: About the company
About the company RMDY is a company that developed a platform which provides a cloud solution enabling medical companies and organizations to quickly and easily transfer their management, treatment and contact with their patients to a digital communication via smartphones. Its list of clients includ
Slide 29: Technological solution
Technological solution RMDY has made the complexity of management simple and easy with friendly and efficient software. In light of fierce competition and fast transition in which companies and medical organizations are required to convert their traditional services into fast, competitive, economic
Slide 30: How does it work?
How does it work? Program manager Nurse/Coach Patient HCP AI BI BOTS Primary care physician 30
Slide 31: The investment
The investment 6% In March 2018 Merchavia invested $500K dollars against the allotment of preferred shares. Currently Merchavia holds about 6% on a fully diluted basis. 31
Slide 32: Significant milestone
Significant milestone A striking example of the company's success are the clinical results of a Diabetic patients trial conducted with the company's systems by medical equipment giant Medtronic in collaboration with IBM: Among 83% of the participants, a The company's systems currently support tens s
Slide 33: The potential
The potential Currently RMDY is developing significantly, both in terms of technology and in terms of recruiting strategic customers in the US. During the next 12 months, RMDY plans to raise a substantial amount of private funding that could constitute a preliminary funding for the initial public of
Slide 34: Games 4 Pain
GAMES 4 PAIN <uecwm GAP
Slide 35: About the company
About the company Games for Pain develops an interactive and adaptive system for the treatment of chronic pain through gaming. The medical technological approach is based on a perception known in the literature, according to which the nervous system is particularly sensitive in chronic pain patients
Slide 36: The Technology
The Technology The system consists of an adaptive stimulator and mobile-based application that will offer specific games for patients to reduce pain levels. The therapeutic approach is based on several well-known studies published in the literature from 2001. The uniqueness of the technology is an a
Slide 37: The investment
The investment 5.7% G4P In October 2018 Merchavia signed an investment agreement in the amount of NIS 600,000 to be made in three installments, with immediate payment of NIS 200,000 and two payments in accordance with milestones. Currently Merchavia holds about 5.7% on a fully diluted basis. G4P 37
Slide 38: Milestones
Milestones The Company's work plan for the next two years during the incubator period includes, inter alia: 1. Design of the product and start of initial production of the device 2. Updating and improving the artificial intelligence algorithm. 3. Conducting a pilot clinical trial in about 30 patient
Slide 39: EFA
EfA ngineering for All gL Mette te Axa IXNN
Slide 40: About the company
About the company EFA develops a device that is used as a portable diagnostic laboratory to perform CBC and other blood tests. The diagnostic system addresses the global need to minimize the overuse of antibiotics, and combines several advantages of ease of use and advanced technology, including a s
Slide 41: The Technology
The Technology The developed system is a combination of several technological elements: 1. A disposable chip that can prepare the blood sample as required by laboratory microscopy tests. 2. A portable electro-optical device with a built-in microscope that can perform automatic microscopy and produce
Slide 42: The investment
The investment 9.09% In March 2019 Merchavia signed an investment agreement in the amount of 1 million NIS to be made in four installments, with immediate payment of 300,000 NIS and 3 payments in accordance with milestones. Currently Merchavia holds 9.09% on a fully diluted basis. 42
Slide 43: Milestones
Milestones The Company's work plan for the next two years during the incubator period includes, inter alia: 1. Development of a single-use chip that can prepare the blood sample as required by laboratory microscopy tests. 2. Completion of the development of a portable electro-optical device with a b
Slide 44: Medical cannabis
Medical cannabis In October 2018, the board of directors of Merchavia decided to expand Merchavia's investment activity to investments in companies that engage in research and development in the field of medical cannabis. 44
Slide 45: Signing of an investment agreement with Veoli
Signing of an investment agreement with Veoli At the deal closing date, Merchavia will invest a total of $400,000 for approximately 20% of issued and paid up share capital of Veoli. Veoli was established in Sanara Ventures technological incubator, in which the Teva Industries and Philips are partner
Slide 46: The investment
The investment 20% In March 2019 Merchavia signed an investment agreement in the amount of $400,000. On the deal closing date Merchavia is expected to hold 20% on a fully diluted basis. 46
Slide 47: Milestones
Milestones The company is planning to launch the product for marketing within 18 months 1. Adaptation of the existing drug delivery system to cannabis oil. 2. Closing the production file and moving to production. 3. Conducting clinical trials to prove pharmacokinetics (effect of the substance on the
Slide 48: Upcoming events in the companies over the next 18 months
Upcoming events in the companies over the next 18 months 1. Establishment and 1. Completion of a commercialization consolidation of the agreement for prostate cancer test and 1. Adaptation of the 1. Completion of Company's overall initiation of marketing. existing drug single-use chip sales system.
Slide 49: Thank you
Merchavia Holdings and Investments Ltd. Presentation for Investors Thank you 49
Merchavia Holdings and Investments — Investor Presentation (April 2019) on 6ix